Recurrent Malignant Testicular Germ Cell Tumor Completed Phase 2 Trials for Ondansetron (DB00904)

IndicationStatusPhase
DBCOND0028803 (Recurrent Malignant Testicular Germ Cell Tumor)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00795769Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell TransplantSupportive Care